Dose escalation in Part I of the study shall follow a modified Fibonacci dose escalation design, with 100% dose escalations allowed until a Grade 2 toxicity that is considered related to treatment is confirmed (as defined by the NCI CTCAE v3.0). If this occurs, future escalations shall then be incremental (67%, 50%, 40%, 33%, etc), until the MAD is confirmed. Intermediate dose levels may be evaluated if indicated by the acquired safety or PK data.